David Saggau, MD
Ophthalmology · West Des Moines, IANPI 1124010913
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $2,403 of the $2,801 with a category attached, or 85.8%. US Retina LLC accounts for 85.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $1,101 and has fallen 93.5% since, to $72 in 2025.
Across 17 payments — averaging $164.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$2K
- Alcon$150
- Sight Sciences, Inc.$71
- Bausch & Lomb Americas Inc.$61
- Apellis Pharmaceuticals, Inc.$49
- Regeneron Healthcare Solutions, Inc.$46
- plus $21 from 1 others
What the payments were for
- Food & beverage$39814%
- Ownership interest$2,40386%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 5 | $2,403 |
| Alcon | 1 | $150 |
| Sight Sciences, Inc. | 2 | $71 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Apellis Pharmaceuticals, Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Novartis | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$150
How this compares
$2,801 in reported general payments places this provider in the 65th percentile of 172 ophthalmology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 91 | $4,113 |
| Brinzolamide | 19 | $3,716 |
| Dorzolamide Hcl | 49 | $825 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 51 | $672 |
| MoxifloxacinMoxifloxacin Hcl | 28 | $655 |
| Timolol Maleate | 36 | $282 |
| Prednisone | 22 | $195 |
| Latanoprost | 15 | $107 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in West Des Moines
- Jared NielsenWest Des Moines$117K
- Matthew RauenWest Des Moines$108K
- Kyle AllimanWest Des Moines$8K
- Frederick BlodiWest Des Moines$6K
- Valerie KounkelWest Des Moines$4K
- George ClavennaWest Des Moines$4K
- Andrew SteffensmeierWest Des Moines$3K
- Matthew RaeckerWest Des Moines$3K
- Mohamed HassanWest Des Moines$3K
- Steven JohnsonWest Des Moines$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.